Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Forsteo in Anorexia Nervosa with Low Bone Mineral Density
NCT01801397Phase 3Unknown
- Sponsor
- University of Zurich
- Start
- Mar 2014
- Primary completion
- Jun 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of teriparatide in osteoporosis, sponsored by University of Zurich. Primary endpoint: Bone Mineral Density at 24 months. Status: unknown.
02
Drugs
teriparatide
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT01801397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01801397.